Media Releases
- Mar 02, 2022MedX Health and Health Partners Announce Agreement to Launch MedX’s Teledermatology Screening Platform in the United Kingdom
- Jan 20, 2022MedX Health Corp. Launches DermSecure Screening Services with Medicure Clinic
- Jan 17, 2022MedX Health Corp. Announces Addition of Three New Screening Services Locations Across Ontario
- Nov 30, 2021MedX Health Corp. and London Medical Laboratory Ltd. Announce Commercialization Pilot of World-Class Teledermatology Screening Platform in the United Kingdom
- Nov 29, 2021MedX Health Corp. Announces Third Quarter 2021 Results
Reports and Filings
- Jul 14, 2020Interim Financial Statements/Report – English
- Jul 14, 2020MD&A - English
- Jun 12, 2020Audited Annual Financial Statements - English
- Jun 12, 2020MD&A - English
- May 30, 2020MD&A - English
- Nov 27, 2019Interim Financial Statements/Report – English
- Nov 27, 2019MD&A - English
- Aug 28, 2019Interim Financial Statements/Report – English
- Aug 28, 2019MD&A - English
- May 30, 2019Interim Financial Statements/Report – English
MedX is committed to technology that is safe and effective.
The safety and effectiveness for patients is our first priority. SIAcopy is rapid, patient-friendly, accurate, easy to use, and practice-friendly. SIAscopy has been used for over 12 years and is supported by over 15 published clinical studies and 24 in vivo clinical posters. MedX Health designs, develops and distributes innovative imaging and software technologies that have been tested for safety and effectiveness and have been cleared and licensed for use in Canada, European Union, and Australia.
The technology has gone through stringent testing and it has been cleared for sale by the following regulatory bodies: Health Canada, CE and ARTG.